The MALDI-TOF-MS(matrix assisted laser desorption ionization time of flight mass spectrometry)method was used for genotyping of SNP loci in PPARG gene, detection and analysis of 100 cases of(50 controls, 50 cases)unrelated Kirgiz populations, to investigate the relationship between the SNPs of PPARG gene with type 2 diabetes mellitus(DM)in Xinjiang Kirgiz population. The results showed that 23 SNPs have polymorphism(MAF≥0.05)among the selected 31 SNP loci. There were statistical differences in blood pressure, hip circumference, blood sugar, TH, and LDL between the case and control groups(P<0.01). There were significant differences in genotypes and allele frequency distribution of SNPs rs1801282, rs1899951, rs2881654, and rs2972162 between the case and control groups(P<0.05). Logistics regression analysis displays significant differences in allele frequency between the two groups (OR value is 2.639, 2.639, 1.774, 2.639, P<0.05). There were significant differences in genotypes frequency of SNPs rs1899951, rs2292101, rs2881654, rs6782475, and rs1801282 between the men and women control group(P<0.05). The results also showed that the PPARG gene SNPs rs1801282, rs1899951, and rs2881654 have correlation with type 2 DM in Xinxiang Kirgiz people.
RUZI Zohra, SONG Manshu, NIZAM Yiliham, ZHAO Feifei, MAITIYUSUP Dolkun
. Genetic polymorphism of 31 SNPs in PPARG gene and their correlation with type 2 diabetes in Kirgiz population[J]. Science & Technology Review, 2015
, 33(24)
: 75
-82
.
DOI: 10.3981/j.issn.1000-7857.2015.24.013
[1] Huang G M, Huang K Y, Lee T Y, et al. An interpretable rule-based diagnostic classification of diabetic nephropathy among type 2 diabetes patients[J]. BMC Bioinformatics, 2015, 16(Suppl 1): S5.
[2] Stagi S, Lapi E, Seminara S. Salvatore seminar a significantly reduces body mass index and hyper insulinism and may decrease the risk of type 2 diabetes mellitus (T2DM) in obese children and adolescents with family history of obesity and T2DM[J]. Italian Journal of Pediat-rics, 2015, 41(10):1-12.
[3] Jung J A, Lee S Y, Kim T E, et al. lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmaco-kinetics and pharmacodynamics of warfarin[J]. Drug Design, Develop-ment and Therapy, 2015, 2(9): 737-743.
[4] Rastegari A, Rabbani M, Sadeghi H M. Association of KCNJ11 (E23K) gene polymorphism with susceptibility to type 2 diabetes in Iranian pa-tients[J]. Advanced Biomedical Research, 2015, 4(1): 1-13.
[5] Liu N J, Wu H H, Li Y L. An analysis of the association between a polymorphism of KCNJ11 and diabetic retinopathy in a Chinese Han population[J]. European Journal of Medical Research, 2015, 20(1): 1-7.
[6] Zhang Y, Guo X, Guo J, et al. Lactobacillus casei reduces susceptibili-ty to type 2 diabetes via microbiota-mediated body chloride ion influx[J]. Scientific Rreports, 2014, 4.
[7] 孙亮, 王沥. 中国北方人2 型糖尿病易感基因的PPARGC1的分子遗 传学研究[D]. 北京: 中国科学院遗传与发育生物学研究所, 2007. Sun Liang, Wang Li. Molecular genetics study on PPARGC1 as a sus-ceptible gene to type 2 diabetes in northern Chinese[D]. Beijing: Insti-tute of Genetics and Developmental Biology, Chinese Academy of Sci-ences, 2007.
[8] 骆文书. 过氧化物酶体增殖物激活受体α δ γ 单核苷酸多态性以及单 体型与BMI和腰围的关系[D]. 苏州: 苏州大学, 2012. Luo Wenshu. Study on genetic polymorphism of peroxisome proliferatoractivated receptors and haplotype on body mass index and waist circum-ference[D]. Suzhou: Suzhou University, 2012.
[9] 海波, 解惠坚, 郭志荣, 等. 过氧化物酶体增殖物激活受体以及基因一 基因交互作用与脂质蓄积指数水平的关系[J]. 中华流行病学杂志, 2013, 11(34): 1071-1076. Hai Bo, Xie Huijian, Guo Zhirong, et al. Association of both peroxi-some proliferator-activated receptor,gene-gene interactios and the lipid accumulation product[J]. Chinese Journal of Epidemiology, 2013, 11 (34): 1071-1076.
[10] Wang L, Waltenberger B. Natural product agonists of peroxisome pro-liferator-activated receptor gamma (PPARγ ): A review[J]. Biochemical Pharmacology, 2014, 92(1): 73-89.
[11] 姬森林, 黄青阳.PPARγ 变异与复杂疾病[J]. 遗传, 2006, 28(8): 993-1001. Ji Senlin, Huang Qingyang. PPARγ variants and complex diseases[J]. Hereditas, 2006, 28(8): 993-1001.
[12] Wang L, Waltenberger B, Pferschy-Wenzig E M, et al. Natural prod-uct agonists of peroxisome proliferator-activated receptor gamma (PPARγ ): A review[J]. Biochemical Pharmacology, 2014, 92(1): 73-89.
[13] Wang T, Xu J, Yu X, et al. Peroxisome proliferator-activated receptor γ in malignant diseases[J]. Critical Reviews in Oncology/Hematology, 2006, 58(1): 1-14.
[14] Usuda D, Kanda T. Peroxisome proliferator-activated receptors for hy-pertension[J]. World Journal of Cardiology, 2014, 6(8): 744.
[15] Lai L, Wang M, Martin O J, et al. A role for peroxisome proliferatoractivated receptor γ coactivator 1 (PGC-1) in the regulation of cardiac mitochondrial phospholipid biosynthesis[J]. Journal of Biological Chem-istry, 2014, 289(4): 2250-2259.
[16] Oger F, Dubois-Chevalier J, Gheeraert C, et al. Peroxisome prolifera-tor-activated receptor γ regulates genes involved in insulin/insulinlike growth factor signaling and lipid metabolism during adipogenesis through functionally distinct enhancer classes[J]. Journal of Biological Chemistry, 2014, 289(2): 708-722.
[17] Ruchat S M, Rankinen T, Weisnagel S J, et al. Improvements in glu-cose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: Results from the HERITAGE family study[J]. Diabetologia, 2010, 53(4): 679-689.
[18] Tariq K, Malik S B, Ali S H B, et al. Association of Pro12Ala polymor-phism in peroxisome proliferator activated receptor gamma with prolif-erative diabetic retinopathy[J]. Molecular Vision, 2013, 19(5): 710-717.
[19] Pei Q, Huang Q, Yang G, et al. PPAR-γ2 and PTPRD gene polymor-phisms influence type 2 diabetes patients' response to pioglitazone in China[J]. Acta Pharmacologica Sinica, 2013, 34(2): 255-261.
